Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials
Research Square
Abstract
Semaglutide confers cardiovascular and kidney benefits and reduces all-cause mortality in high-risk populations. Whether biological-age metrics capture these effects and provide mechanistic insight remains unclear.
- Semaglutide
- Brain biological age
- C-reactive protein
- Cardiometabolic disease
- Cardiometabolic disease-risk score
- Humans
The paper
Maria Dermit, Helen M Colhoun, Ludger J.E. Goeminne, Alejandro Aguayo‐Orozco
Show 8 more authors
D H Ryan, Kasper Adelborg, Dylan Belmont-Rausch, Kristoffer Jensen Kolnes, Filip Krag Knop, Sarah Amandine Caroline Voisin, Vadim N. Gladyshev, Lotte Bjerre Knudsen,Novo Nordisk Research and Development UK Limited (UK R&D) · Novo Nordisk (Denmark)
Research Square · 22 Sep 2026 · CC BY · Preprint, not peer-reviewed
